• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Zoom’s stock drop likely nixed Five9 deal, say analysts

October 1, 2021 by David Barret Leave a Comment

October 1, 2021

By Aniruddha Ghosh

(Reuters) – A slump in Zoom Video Communications Inc’s share price likely limited its ability to sweeten a nearly $15 billion all-stock offer for call center software firm Five9 and led to the deal’s collapse, Wall Street analysts said on Friday.

Five9 shareholders on Thursday voted down the sale to Zoom, denting the company’s efforts to diversify its offerings as growth slows in its virtual conferencing business after a boom during the pandemic.

While some analysts expected Zoom to raise its offer to address Five9 shareholder worries about the price, others said an almost 30% drop in Zoom shares since July on the back of slowing growth only dampened the prospects.

Under the deal terms, Five9 shareholders would have received 0.5533 Zoom share for each share held. The terms then implied a 12.8% premium over Five9’s market price.

“The deal was negatively perceived from the beginning given the small premium and all-stock structure,” Jefferies analyst Samad Samana said in a note to clients. “ZM’s stock declining 28% since the announcement only compounded the issues and likely made revising the terms difficult as well.”

The deal – which would have been Zoom’s biggest-ever purchase if completed – was also opposed by shareholder proxy advisory firms ISS and Glass Lewis. The firms had recommended that Five9 shareholders vote against the deal, citing growth concerns and dual-class shares.

“While we think the deal made strategic sense for both companies over the long term, the variable deal tied to volatile (Zoom) shares was not an economically attractive deal for (Five9) shareholders at this time,” Piper Sandler analysts said.

Analysts at Barclays blamed the fall in Zoom’s share price and possible regulatory scrutiny for the deal falling through.

A U.S. Justice Department panel had been reviewing the deal over possible national security concerns, though analysts had said it was unlikely the deal would be scrapped as a result.

“(Our) conversations, especially with event-driven investors, suggest that they believe Five9 was important enough to Zoom that they would ultimately bump/sweeten the offer for Five9,” J.P. Morgan analysts said.

“Obviously, the recent pullback in stock prices for premium valuation software stocks makes the current situation all the more complicated.”

Zoom’s shares gained 1.6% to $265.79 in premarket trading, while Five9’s stock was down about 3% at $155.

(Reporting by Aniruddha Ghosh in Bengaluru; Editing by Sachin Ravikumar and Sriraj Kalluvila)

Source Link Zoom’s stock drop likely nixed Five9 deal, say analysts

David Barret
David Barret

Related posts:

  1. Australia central bank to stick with tapering plans, or maybe not
  2. Japan firms see economy recovering to pre-COVID level in FY2022
  3. Air New Zealand studying how to add low-emissions planes to fleet
  4. ECB’s Lagarde flags bottlenecks, energy and virus as key risks

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • “Wholly Unexpected”: First-Ever Fossil Paranthropus Hand Raises Questions About Earliest Tool Makers’ Identity
  • For Centuries, Nobody Knew Why Swiss Cheese Has Holes. Then, The Mystery Was Solved.
  • Scientists Studied The Infamous “Chicago Rat Hole” And They Have Some Bad News
  • Massive 166-Million-Year-Old Sauropod Footprints Become The Longest Dinosaur Trackway In Europe
  • Do Spiders Dream? “After Watching Hundreds Of Spiders, There Is No Doubt In My Mind”
  • IFLScience Meets: ESA Astronaut Rosemary Coogan On Astronaut Training And The Future Of Space Exploration
  • What’s So Weird About The Methuselah Star, The Oldest We’ve Found In The Universe?
  • Why Does Red Wine Give Me A Headache? Many Scientists Blame It On The Grape Skins
  • Manta Rays Dive Way Deeper Than We Thought – Up To 1.2 Kilometers – To Explore The Seas
  • Prof Brian Cox Explains What He Finds “Remarkable” About Interstellar Object 3I/ATLAS Story
  • Pioneering “Pregnancy Test” Could Identify Hormones In Skeletons Over 1,000 Years Old
  • The First Neolithic Self-Portrait? Stony Human Face Emerges In 12,000-Year-Old Ruins At Karahan Tepe
  • Women Are Diagnosed With ADHD 5 Years Later Than Men, Even With Worse Symptoms
  • What Is Cryptozoology? We Explore The History And Mystery Of This Controversial Field
  • The Universe’s “Red Sky Paradox” Just Got Darker: Most Stars Might Never Host Observers
  • Uranus And Neptune May Not Be “Ice Giants” But The Solar System’s First “Rocky Giants”
  • COVID-19 Can Alter Sperm And Affect Brain Development In Offspring, Causing Anxious Behavior
  • Why Do Spiders’ Legs Curl Up Like That When They’re Dead?
  • “Dead Men’s Fingers” Might Just Be The Strangest Fruit On The Planet
  • The South Atlantic’s Giant Weak Spot In The Earth’s Magnetic Field Is Growing
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version